Sexual enhancement supplement recalled by manufacturer
Ebek, Inc., is conducting a voluntary nationwide recall of its supplement product sold under the name Liviro3. Lab analysis of Liviro3 samples conducted by the FDA found the product contains the phosphodiesterase type-5 inhibitor tadalafil, making Liviro3 an unapproved drug.
Ebek, Inc., is conducting a voluntary nationwide recall of its supplement product sold under the name Liviro3. Lab analysis of Liviro3 samples conducted by the FDA found the product contains the phosphodiesterase type-5 inhibitor tadalafil, making Liviro3 an unapproved drug. The agency described the product as a threat to consumers because tadalafil may interact with nitrates found in some prescription drugs, and may lower blood pressure to dangerous levels.
The FDA advises that tadalafil may cause side effects, such as headaches and flushing.
Liviro3 is sold in 10-tablet boxes or 20-tablet plastic bottles. The product label warns consumers with high blood pressure not to ingest the product, but does not state that it contains tadalafil.
No illnesses have been reported to the company in connection with the product.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
